JP2017515795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515795A5 JP2017515795A5 JP2016559818A JP2016559818A JP2017515795A5 JP 2017515795 A5 JP2017515795 A5 JP 2017515795A5 JP 2016559818 A JP2016559818 A JP 2016559818A JP 2016559818 A JP2016559818 A JP 2016559818A JP 2017515795 A5 JP2017515795 A5 JP 2017515795A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- acid sequence
- seq
- amino acid
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 12
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163081.4 | 2014-04-01 | ||
| EP14163081 | 2014-04-01 | ||
| PCT/EP2015/057257 WO2015150491A1 (en) | 2014-04-01 | 2015-04-01 | An isolated donor mhc-derived peptide and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219661A Division JP2020055845A (ja) | 2014-04-01 | 2019-12-04 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515795A JP2017515795A (ja) | 2017-06-15 |
| JP2017515795A5 true JP2017515795A5 (cg-RX-API-DMAC7.html) | 2018-03-01 |
Family
ID=50390011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559818A Ceased JP2017515795A (ja) | 2014-04-01 | 2015-04-01 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
| JP2019219661A Pending JP2020055845A (ja) | 2014-04-01 | 2019-12-04 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019219661A Pending JP2020055845A (ja) | 2014-04-01 | 2019-12-04 | 単離されたドナーｍｈｃ由来ペプチド及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10105425B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3126377B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2017515795A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2749073T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015150491A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4219524A3 (en) * | 2016-04-06 | 2023-10-18 | immatics biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers |
| WO2019099788A1 (en) * | 2017-11-16 | 2019-05-23 | Benaroya Sesearch Institute At Virginia Mason | Antigen-specific t regulatory cell assay |
| EP3894543A1 (en) * | 2018-12-14 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563485A1 (en) | 1992-03-30 | 1993-10-06 | Schering-Plough | In vitro generation of human dendritic cells and uses thereof |
| AU687733B2 (en) | 1992-04-01 | 1998-03-05 | Rockefeller University, The | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| PL1642905T3 (pl) * | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
-
2015
- 2015-04-01 ES ES15713503T patent/ES2749073T3/es active Active
- 2015-04-01 US US15/300,896 patent/US10105425B2/en not_active Expired - Fee Related
- 2015-04-01 JP JP2016559818A patent/JP2017515795A/ja not_active Ceased
- 2015-04-01 EP EP15713503.9A patent/EP3126377B1/en active Active
- 2015-04-01 WO PCT/EP2015/057257 patent/WO2015150491A1/en not_active Ceased
-
2019
- 2019-12-04 JP JP2019219661A patent/JP2020055845A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| D’Alessio et al. | Reparative T lymphocytes in organ injury | |
| AR127116A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| JP7731656B2 (ja) | Ｒｎａ癌ワクチン | |
| JP2013521789A5 (cg-RX-API-DMAC7.html) | ||
| JP2018523668A5 (cg-RX-API-DMAC7.html) | ||
| JP2019509029A5 (cg-RX-API-DMAC7.html) | ||
| JP2020513191A (ja) | 細胞を樹状細胞または抗原提示細胞にリプログラムするための組成物、その方法および使用 | |
| JP2017516752A5 (cg-RX-API-DMAC7.html) | ||
| Chua et al. | An engineered probiotic produces a type III interferon IFNL1 and reduces inflammations in in vitro inflammatory bowel disease models | |
| JP2015510393A5 (cg-RX-API-DMAC7.html) | ||
| EP2030984A4 (en) | DERIVED FROM SPARC CANCER EXHAUSTANTEPEPTIDE AND PHARMACEUTICALS CONTAINING THEREOF | |
| JP2022513019A (ja) | 新規の酸化還元酵素モチーフを有する免疫原性ペプチド | |
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| JP2017515795A5 (cg-RX-API-DMAC7.html) | ||
| FI3380115T3 (fi) | Peptidejä piwil1:stä | |
| WO2015150492A3 (en) | An isolated donor mhc-derived peptide and uses thereof | |
| JP5829517B2 (ja) | 不溶性蛋白質及び／又はペプチドの可溶化方法 | |
| ES2905757T3 (es) | Métodos y composiciones para el tratamiento del melanoma | |
| JP2012526519A5 (cg-RX-API-DMAC7.html) | ||
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие | |
| EP3868778A3 (en) | Cdc45l peptides and vaccines including the same | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| Hsieh et al. | A GMCSF and IL7 fusion cytokine leads to functional thymic‐dependent T‐cell regeneration in age‐associated immune deficiency | |
| UA124331C2 (uk) | Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу | |
| Ayala et al. | Commensal bacteria promote type I interferon signaling to maintain immune tolerance |